Varda Shalev Net Worth

The estimated Net Worth of Varda Shalev is at least $231 Tisíc dollars as of 2 September 2024. Varda Shalev owns over 12,872 units of Teva- Pharmaceutical Industries stock worth over $231,181 and over the last 3 years Varda sold TEVA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Varda Shalev TEVA stock SEC Form 4 insiders trading

Varda has made over 1 trades of the Teva- Pharmaceutical Industries stock since 2024, according to the Form 4 filled with the SEC. Most recently Varda exercised 12,872 units of TEVA stock worth $231,181 on 2 September 2024.

The largest trade Varda's ever made was exercising 12,872 units of Teva- Pharmaceutical Industries stock on 2 September 2024 worth over $231,181. On average, Varda trades about 3,218 units every 0 days since 2021. As of 2 September 2024 Varda still owns at least 12,872 units of Teva- Pharmaceutical Industries stock.

You can see the complete history of Varda Shalev stock trades at the bottom of the page.

What's Varda Shalev's mailing address?

Varda's mailing address filed with the SEC is C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, L3, 6944020.

Insiders trading at Teva- Pharmaceutical Industries

Over the last 7 years, insiders at Teva- Pharmaceutical Industries have traded over $31,332,399 worth of Teva- Pharmaceutical Industries stock and bought 967,500 units worth $16,473,820 . The most active insiders traders include Sol J Barer, Tal Zvi Zaks a Roberto Mignone. On average, Teva- Pharmaceutical Industries executives and independent directors trade stock every 9 days with the average trade being worth of $636,538. The most recent stock trade was executed by Varda Shalev on 2 September 2024, trading 12,872 units of TEVA stock currently worth $231,181.

What does Teva- Pharmaceutical Industries do?

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.

Complete history of Varda Shalev stock trades at Pluri Inc a Teva- Pharmaceutical Industries

Teva- Pharmaceutical Industries executives and stock owners

Teva- Pharmaceutical Industries executives and other stock owners filed with the SEC include:

• Kaare Schultz,
  President, Chief Executive Officer, Director
• Kare Schultz,
  Pres, CEO & Director
• Mark Sabag,
  Executive Vice President, Chief Human Resources Officer and Global Communications and Brand
• Hafrun Fridriksdottir,
  Executive Vice President - Global R&D
• Brendan O'Grady,
  Executive Vice President - North America Commercial
• Gianfranco Nazzi,
  Executive Vice President - International Markets Commercial
• Dr. Hafrun Fridriksdottir,
  Exec. VP of Global R&D
• Gianfranco Nazzi,
  Exec. VP of International Markets Commercial
• Eric Drape,
  Exec. VP of Global Operations
• Eliyahu Sharon Kalif,
  Exec. VP & CFO
• Sol Barer,
  Independent Chairman of the Board
• Nechemia Peres,
  Independent Director
• Gerald Lieberman,
  Independent Director
• Amir Elstein,
  Independent Director
• Roberto Mignone,
  Independent Director
• Rosemary Crane,
  Independent Director
• Jean-Michel Halfon,
  Independent Director
• Perry Nisen,
  Independent Director
• Ronit Satchi-Fainaro,
  Independent Director
• Eliyahu Kalif,
  Chief Financial Officer, Executive Vice President
• Kevin Mannix,
  Senior Vice President, Investor Relations
• Janet Vergis,
  Independent Director
• Abbas Hussain,
  Independent Director
• David Stark,
  Executive Vice President, Chief Legal Officer
• Eric Drape,
  Executive Vice President - Global Operations
• Sven Dethlefs,
  Executive Vice President - Global Marketing & Portfolio
• Richard Daniell,
  Executive Vice President - European Commercial
• Eli Shani,
  Exec. VP of Global Marketing & Portfolio
• Galia Inbar,
  Exec. VP, Chief HR Officer and Head of Global Communications, Brand & ESG
• David M. Stark,
  Exec. VP & Chief Legal Officer
• Amir Weiss,
  Sr. VP & Chief Accounting Officer
• Lori Queisser,
  Sr. VP & Global Compliance Officer
• Andrew J. Weil CPA,
  Chief Accounting Officer
• Eric Drapé,
  Exec. VP of Global Operations
• Iris Beck Codner,
  EVP Global Brand&Communication
• Kare Schultz,
  President and CEO
• Michael James Mc Clellan,
  EVP, Chief Financial Officer
• Notaristefani Carlo De,
  Executive VP Global Operations
• Placid Jover,
  See "Remarks"
• Deborah A Griffin,
  Chief Accounting Officer
• Varda Shalev,
  
• Dan S Suesskind,
  Director
• Murray A Goldberg,
  Director
• Dov Bergwerk,
  Acting Chief Legal Officer
• David R. Mc Avoy,
  EVP, Chief Legal Officer
• Andrew Weil,
  Chief Accounting Officer
• Galia Inbar,
  See "Remarks"
• Eli Shani,
  EVP,Global Marketing&Portfolio
• Angus Grant,
  EVP, Business Development
• Eric A Hughes,
  See "Remarks"
• Vikki L Conway,
  See "Remarks"
• Christine Fox,
  EVP, Head of U.S. Commercial
• Amir Weiss,
  Chief Accounting Officer
• Richard D Francis,
  President and CEO
• Matthew Shields,
  EVP, Global Operations
• Tal Zvi Zaks,